Source: Eur Respir J, 52 (6) 1801848; 10.1183/13993003.01848-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Samy Suissa, Amnon Ariel. Triple therapy trials in COPD: a precision medicine opportunity. Eur Respir J, 52 (6) 1801848; 10.1183/13993003.01848-2018

Member's Comments

No comment yet.

Related content which might interest you: What is the scientific and clinical rationale? Triple therapy in COPD patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 Triple therapy in COPD: Oportunities and challenges Source: Short Video Statement 2020 Year: 2020 A personalised medicine approach to ICS use in COPD Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care Year: 2019 Initial trials of precision medicine approaches in airway disease Source: ERS Research Seminar 2017 – Precision medicine in airway diseases Year: 2017 Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021 Year: 2022 How to treat IPF: lessons from the NIH-IPF-Net treatment trials Source: International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century" Year: 2014 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis Source: Eur Respir J, 52 (6) 1801586; 10.1183/13993003.01586-2018 Year: 2018 Feasibility, acceptability and safety of downhill walking during pulmonary rehabilitation for patients with COPD: Results from a randomised controlled trial Source: International Congress 2016 – Effects of exercise training interventions in chronic respiratory disease Year: 2016 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 How to increase the value of randomised trials in COPD research Source: Eur Respir J 2009; 34: 552 Year: 2009 Guidelines versus clinical practice in the treatment of COPD: a reappraisal Source: Eur Respir J 2006; 27: 656 Year: 2006 Evaluation of the use of e-learning in training management of asthma and COPD in general medicine. Source: International Congress 2017 – Medical education, web and internet Year: 2017 Interval training as an alternative rehabilitative modality to continuous exercise in patients with COPD: a randomized trial Source: Eur Respir J 2001; 18: Suppl. 33, 187s Year: 2001 Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study Source: Eur Respir J 2006; 28: Suppl. 50, 613s Year: 2006 Clinical effectiveness of triple therapy in the management of COPD: A systematic review Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD Year: 2010 Exercise and cardiovascular benefit in subjects with COPD: the need for randomised trials Source: Eur Respir J 2014; 44: 263-264 Year: 2014 Exercise and cardiovascular benefit in subjects with COPD: the need for randomised trials Source: Eur Respir J 2014; 44: 264-265 Year: 2014 Triple therapy versus dual bronchodilation and long-acting ß-agonists/inhaled corticosteroids in COPD: accumulating evidence from network meta-analyses Source: International Congress 2019 – Therapeutic breakthrough Year in review Year: 2019